History

2017

Suven Life sciences announces initiation of Phase 1 Clinical Trial and First Dosing of SUVN-911, a nAChRs antagonist for MDD

2016

SUVEN-D4010 Phase 1 clinical trial completed successfully in USA.

Suvenís Pashamylaram unit successfully completed US FDA inspection.

2015

Suven Life Sciences bags Pharmexcil's "Gold Patent Award"

SUVN≠502 - Completed phase 1b clinical trial under US-IND.

SUVN≠G3031 - Completed SAD and MAD studies of phase 1 clinical trial under US≠IND

SUVN-D4010 Ė IND filed in USA

Suven facility at JNPC, Vishakapatnam, Andhra Pradesh has commenced commercial operations

SUVN-D4010 for Cognition in Alzheimerís disease commenced Phase 1 Clinical Trial in USA under US-IND126099

Suven has created a wholly owned subsidiary, Suven, Inc., a Delaware Company in USA

Suven initiates Phase 2A trial of SUVN-502 in USA

2014

Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award

Suven Life Sciences bags Pharmexcil’s “Gold Patent Award” for NCE’s and “Outstanding Export Performance Award” for Contract Research and Manufacturing.

SUVEN’S PASHAMYLARAM’S UNIT RECEIVES US FDA ACCEPTANCE

2012

Suven Life Sciences bags Pharmexcil’s “Platinum Patent Award”

Suven to Present at Alzheimer's Association International Conference (AAIC)

2011

Suven Life Sciences bags Pharmexcil’s Gold “Patent Award”

Suven Participating at 4th CNS Partnering & Deal Making Conference in USA

Suven Life Sciences bags “Bio-Excellence Award at Bangalore India Bio 2011”

Suven’s partnering and fund-raising activity at J.P. Morgan Healthcare Conference 2011

2010

Suven Life Sciences bags Pharmexcil's Gold “Patent Award”

Suven Life Sciences presenting at International Conference on Alzheimer’s Disease (ICAD)

Suven’s partnering and fundraising activity at C21 BioVentures

2009

Suven achieves 1st Milestone payment in Drug Discovery collaboration

SUVEN’S UNIT- I RECEIVES US FDA ACCEPTANCE.

Suven participation at Biotech Showcase 2009.

2008

Suven granted Certificate of Suitability (CEP) for Tamsulosin Hydrochloride

Suven Establishes second CNS Drug Discovery Collaboration with Lilly

2007

Suven obtains 1st Product Patent from US Patent office

Suven enters into collaboration with University of Minnesota to develop drugs to treat HIV infection

Suven Unit III cGMP facility accepted by USFDA for manufacture of API's

2006

All the units got Certification for ISO 9001 , ISO 14001, OHSAS 18001

2005

Suven Awarded Phase III Clinical study for Chronic Low Back pain.

Suven Awarded 2005 - Partner of Choice in Drug Discovery for CNS by Frost & Sullivan

2004

Gets ISO 14001:1996 certification for Unit - 1 (Suryapet) and Unit - 2 (Jeedimetla)

2003

Name changed to Suven Life Sciences Limited

Acquired assets of New Jersey, USA based Synthon Chiragenics Corporation

2002

cGMP Lab at SRC commissioned

2001

Borregaard takes equity stake

Recognition of SRC as in-house R & D unit by Department of Scientific & Industrial Research (DSIR), India

New Suven Research Center (SRC) inaugurated at Hyderabad

1999

Acquired a Drug Unit at Hyderabad, converted into Research center and Pilot Plant

1997

ISO 9002 Certification

1996

First sale from 'CRAMS'

1995

Went Public (IPO)

1994

Initiation of 'CRAMS' business model (Contract Research And Manufacturing Services)

1992

Commenced export of Fine Chemical Intermediates

1991

Expanded into Fine Chemical Intermediates

1990

Commenced Operations

1989

Incorporation as Suven Pharmaceuticals Pvt. Ltd.